Tessera Biotech has engineered a compact bioreactor and control software to enable hospitals to manufacture CAR-T and NK cell therapies on-site, eliminating multi-week manufacturing delays. The team includes immunologists and bioengineers from ANU and is based in Canberra's emerging biotech corridor. The first installation is underway at a major Australian cancer center.